Sponsors (2)
The bill centralizes federal leadership and public resources to identify and address biomanufacturing supply‑chain vulnerabilities and help small firms scale, at the cost of added administrative expense and risks around sensitive information-sharing and supplier disruptions if protections and industry cooperation are inadequate.
Taxpayers and small biomanufacturers gain biennial assessments and prioritized action plans that identify critical input chokepoints and strategies to diversify suppliers, reducing reliance on foreign adversaries and strengthening supply‑chain resilience.
Domestic biomanufacturers and suppliers get a dedicated Commerce lead to identify supply‑chain chokepoints and opportunities to strengthen domestic production, improving industry competitiveness.
Small businesses and state/local stakeholders get clearer federal points of contact and a consolidated public web resource, making it easier to navigate commercialization processes and agency guidance.
Small manufacturers, researchers, and the public may get limited benefit if companies withhold nonpublic supply‑chain information, and publicly identifying vulnerabilities (even in aggregated form) risks exposing sensitive details unless strict protections are enforced.
Small manufacturers could face higher costs or longer lead times if prioritizing reduced reliance on 'foreign adversaries' forces reshoring or changes to established supplier relationships.
Taxpayers may incur additional administrative costs to fund staff, assessments, and maintain the consolidated web resource and interagency coordination required by the program.
Based on analysis of 2 sections of legislative text.
Directs Commerce to appoint a senior official to assess and coordinate federal activities on biomanufacturing competitiveness, identify supply‑chain vulnerabilities and barriers, consult agencies/stakeholders, and publish public resources.
Official title: To direct the Secretary of Commerce to promote competitiveness in biomanufacturing in the United States, identify supply-chain and commercialization vulnerabilities relating to critical biomanufacturing inputs and domestic production capacity, improve transparency regarding Federal processes applicable to biomanufactured products, and for other purposes.
Introduced August 27, 2026 by Robert E. Latta · Last progress August 27, 2026
Creates a senior Commerce Department official to lead federal efforts on biomanufacturing competitiveness, supply‑chain resilience, and commercial scale production of biomanufactured products. The official must assess domestic capacity and inputs, identify barriers and chokepoints (including ties to foreign adversaries), consult with non‑Federal stakeholders and other agencies (including HHS/FDA and EPA), and publish resources and a public web portal. Requires the designated official to complete key assessments and a report within specified timeframes (many items due within 1 year), maintain a public web resource of practices and contacts, and serve as a central coordination point for industry and other non‑Federal entities seeking federal information on biomanufacturing processes and support.